期刊
CURRENT OPINION IN NEUROLOGY
卷 23, 期 1, 页码 4-9出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WCO.0b013e3283352f96
关键词
clinical trials; induced pluripotent stem cell; photoreceptor; retinitis pigmentosa; transplantation
资金
- Health Foundation
- Wellcome Trust
- Medical Research Council
- Royal College of Surgeons of Edinburgh
- National Institute for Health Research (NIHR) Ophthalmology Biomedical Research Centre
- Special Trustees of Moorfields Eye Hospital
- MRC [G0601588] Funding Source: UKRI
- Medical Research Council [G0601588] Funding Source: researchfish
Purpose of review This review will discuss how recent advances with induced pluripotent stem (iPS) cells have brought the science of stem cell biology much closer to clinical application for patients with retinal degeneration. Recent findings The ability to generate embryonic stem cells by reprogramming DNA taken from adult cells was demonstrated by the cloning of Dolly, the sheep, by somatic cell nuclear transfer, over 10 years ago. Recently, it has been shown that adult cells can be reprogrammed directly, without the need for a surrogate oocyte, through the generation of iPS cells. The method of reprogramming has since been optimized to avoid the use of retroviruses, making the process considerably safer. Last year, human iPS cells were isolated from an 80-year-old patient with neurodegenerative disease and differentiated into neurons in vitro. Summary For stem cell therapies, the retina has the optimal combination of ease of surgical access, combined with an ability to observe transplanted cells directly through the clear ocular media. The question now is which retinal diseases are most appropriate targets for clinical trials using iPS cell approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据